ANR Health Care Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: ANR Health Care Private Limited Pharmaceutical Export Portfolio Dataset — 5 Products, $61.1K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

ANR Health Care Private Limited — Pharmaceutical Exporter Profile (2026) | 5 Products, $61.1K Trade | TransData Nexus

ANR Health Care Private Limited

Indian Pharmaceutical Exporter · Biologics & Immunotherapy Specialist · $61.1K Total Trade · DGFT Verified

ANR Health Care Private Limited is an Indian pharmaceutical exporter with a total trade value of $61.1K across 5 products in 4 therapeutic categories. Based on 31 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Etanercept ($32.7K), Ustekinumab ($17.9K), Repaglinide ($6.9K).

ANR Health Care Private Limited — Export Portfolio & Destination Treemap

ANR Health Care Private Limited pharmaceutical export portfolio — 5 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is ANR Health Care Private Limited? — Company Overview & Market Position

ANR Health Care Private Limited is a private limited company incorporated on June 19, 2012, in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U85100DL2012PTC237744. Its authorized and paid-up capital is ₹100,000. The registered office is located at A-2/59 Safdarjung Enclave, New Delhi, Delhi, 110029.

The company operates in the healthcare sector, focusing on human health activities. As of October 25, 2025, the directors are Ankit Srivastava and Neha Srivastava. Ankit Srivastava has been associated with the company since June 6, 2017, while Neha Srivastava has been a director since June 19, 2012.

What Does ANR Health Care Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Etanercept$32.7K 2Ustekinumab$17.9K

Product Portfolio — Top 5 by Export Value

ANR Health Care Private Limited exports 5 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Etanercept	Biologics & Immunotherapy	$32.7K	10	0.1%	6
2	Ustekinumab	Biologics & Immunotherapy	$17.9K	3	1.4%	11
3	Repaglinide	Advanced Diabetes Medications	$6.9K	10	0.1%	8
4	Nilotinib	Advanced Oncology	$2.4K	4	0.2%	6
5	Levodopa Carbidopa	Combination Drugs	$1.1K	4	14.5%	3

ANR Health Care Private Limited exports 5 pharmaceutical products across 4 therapeutic categories with a total export value of $61.1K. The top category is Biologics & Immunotherapy (82.9% of portfolio), followed by Advanced Diabetes Medications (11.4%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

ANR Health Care Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding ANR Health Care Private Limited's manufacturing facilities, including locations, capacities, and specializations, are not publicly available. The company's export data indicates a focus on finished pharmaceutical formulations, suggesting that manufacturing capabilities are aligned with this product line.

3Key Leadership

The key leadership of ANR Health Care Private Limited comprises:

Ankit Srivastava: Director since June 6, 2017.

Neha Srivastava: Director since June 19, 2012.

No additional executive roles or leadership positions are publicly disclosed.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does ANR Health Care Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

ANR Health Care Private Limited's export data indicates shipments to various international markets. However, specific regulatory filings, approvals, and market access statuses in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available. The company's export data does not provide detailed insights into its presence in these regulated markets.

2Emerging Markets

The company's export data does not specify shipments to Africa, Latin America, or Southeast Asia. Without information on WHO prequalification or other certifications, it is challenging to assess ANR Health Care Private Limited's penetration in these emerging markets.

3Geographic Strategy

ANR Health Care Private Limited's export data reveals shipments of finished pharmaceutical formulations across multiple international markets. The company's portfolio is concentrated in five products, indicating a focused product strategy. However, without detailed information on market diversification and strategic direction, a comprehensive assessment of its geographic strategy is limited.

ANR Health Care Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding ANR Health Care Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's export data does not provide insights into its compliance with FDA regulations.

2WHO & EU GMP

Information regarding ANR Health Care Private Limited's WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status is not publicly available. The company's export data does not indicate compliance with these international standards.

3CDSCO & Indian Regulatory

Specific details about ANR Health Care Private Limited's manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), approvals from state drug controllers, and export No Objection Certificates (NOCs) are not publicly disclosed. The company's export data does not provide insights into its compliance with Indian regulatory requirements.

ANR Health Care Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

ANR Health Care Private Limited operates in the pharmaceutical export sector, focusing on finished pharmaceutical formulations. The company's export data indicates a concentrated product portfolio, with the top five products accounting for 100% of its exports. Without specific information on competitors in overlapping categories and market share comparisons, a detailed competitive analysis is not feasible.

2Key Differentiators

ANR Health Care Private Limited's key differentiators include its focus on finished pharmaceutical formulations and a concentrated product portfolio. However, without detailed information on product quality, innovation, and other competitive advantages, a comprehensive assessment of its unique strengths is limited.

3Strategic Position

The company's export data indicates a focus on finished pharmaceutical formulations, suggesting a strategic direction in this product line. However, without detailed information on its approach to generics, specialty drugs, biosimilars, or Contract Development and Manufacturing Organization (CDMO) services, a comprehensive assessment of its strategic position and future outlook is not possible.

Buyer Due Diligence Brief — Evaluating ANR Health Care Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

ANR Health Care Private Limited's export data indicates a total export value of $61,000 USD across 31 shipments, with a portfolio concentrated in five products. The company's export volume and consistency suggest a focused approach to its product offerings. However, without information on reliability indicators such as on-time delivery, product quality, and customer satisfaction, a comprehensive assessment of its supplier performance is limited.

2Certifications to Verify

Importers should verify the following certifications when considering ANR Health Care Private Limited as a supplier:

FDA Registration: To ensure compliance with U.S. regulations.

WHO-GMP Certification: To confirm adherence to international manufacturing standards.

EU GMP Certification: To verify compliance with European manufacturing practices.

Frequently Asked Questions — ANR Health Care Private Limited

How many pharmaceutical products does ANR Health Care Private Limited export from India?

ANR Health Care Private Limited exports 5 pharmaceutical products across 4 therapeutic categories. The top exports are Etanercept ($32.7K), Ustekinumab ($17.9K), Repaglinide ($6.9K), Nilotinib ($2.4K), Levodopa Carbidopa ($1.1K). Total export value is $61.1K.

What is ANR Health Care Private Limited's total pharmaceutical export value?

ANR Health Care Private Limited's total pharmaceutical export value is $61.1K, based on 31 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does ANR Health Care Private Limited cover?

ANR Health Care Private Limited exports across 4 therapeutic categories. The largest are Biologics & Immunotherapy (82.9%, 2 products), Advanced Diabetes Medications (11.4%, 1 products), Advanced Oncology (4.0%, 1 products).

Get Full ANR Health Care Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.